These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9736573)

  • 1. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration.
    Thalhammer F; Schenk P; Burgmann H; El Menyawi I; Hollenstein UM; Rosenkranz AR; Sunder-Plassmann G; Breyer S; Ratheiser K
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2417-20. PubMed ID: 9736573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration.
    Tegeder I; Neumann F; Bremer F; Brune K; Lötsch J; Geisslinger G
    Clin Pharmacol Ther; 1999 Jan; 65(1):50-7. PubMed ID: 9951430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
    Ververs TF; van Dijk A; Vinks SA; Blankestijn PJ; Savelkoul JF; Meulenbelt J; Boereboom FT
    Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration.
    Giles LJ; Jennings AC; Thomson AH; Creed G; Beale RJ; McLuckie A
    Crit Care Med; 2000 Mar; 28(3):632-7. PubMed ID: 10752806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
    Bo SN; Li HL; Zhu X; Yao GQ; Hu YF; Zhai SD; Lu W; Wang SY; Xu YZ; He B
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Mar; 24(3):145-8. PubMed ID: 22401158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure.
    Valtonen M; Tiula E; Backman JT; Neuvonen PJ
    J Antimicrob Chemother; 2000 May; 45(5):701-4. PubMed ID: 10797097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration.
    Bilgrami I; Roberts JA; Wallis SC; Thomas J; Davis J; Fowler S; Goldrick PB; Lipman J
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2974-8. PubMed ID: 20479205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose pharmacokinetics of ofloxacin during continuous venovenous hemofiltration in critical care patients.
    Fuhrmann V; Schenk P; Mittermayer C; El Menyawi I; Ratheiser K; Thalhammer F
    Am J Kidney Dis; 2003 Aug; 42(2):310-4. PubMed ID: 12900813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
    Krueger WA; Neeser G; Schuster H; Schroeder TH; Hoffmann E; Heininger A; Dieterich HJ; Forst H; Unertl KE
    Chemotherapy; 2003 Dec; 49(6):280-6. PubMed ID: 14671427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of levofloxacin in critically ill patients with renal failure: influence of continuous veno-venous hemofiltration.
    Bellmann R; Egger P; Gritsch W; Bellmann-Weiler R; Joannidis M; Dunzendorfer S; Wiedermann CJ
    Int J Clin Pharmacol Ther; 2002 Apr; 40(4):142-9. PubMed ID: 11996208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
    Banyai M; Thalhammer F; El-Menyawi I; Heinz G; Traunmüller F; Siostrzonek P
    Clin Pharmacol Ther; 2000 Apr; 67(4):368-72. PubMed ID: 10801245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem pharmacokinetics in a patient with multiorgan failure from Meningococcemia undergoing continuous venovenous hemodiafiltration.
    Meyer MM; Munar MY; Kohlhepp SJ; Bryant RE
    Am J Kidney Dis; 1999 Apr; 33(4):790-5. PubMed ID: 10196026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose pharmacokinetics of cidofovir in continuous venovenous hemofiltration.
    Vossen MG; Gattringer KB; Jäger W; Kraff S; Thalhammer F
    Antimicrob Agents Chemother; 2014; 58(4):1952-5. PubMed ID: 24419341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
    Isla A; Maynar J; Sánchez-Izquierdo JA; Gascón AR; Arzuaga A; Corral E; Pedraz JL
    J Clin Pharmacol; 2005 Nov; 45(11):1294-304. PubMed ID: 16239363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment.
    Kuti JL; Nicolau DP
    Chemotherapy; 2005 Jul; 51(4):211-6. PubMed ID: 15985760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.
    Krueger WA; Schroeder TH; Hutchison M; Hoffmann E; Dieterich HJ; Heininger A; Erley C; Wehrle A; Unertl K
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2421-4. PubMed ID: 9736574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic evaluation of voriconazole treatment in critically ill patients undergoing continuous venovenous hemofiltration.
    Radej J; Krouzecky A; Stehlik P; Sykora R; Chvojka J; Karvunidis T; Novak I; Matejovic M
    Ther Drug Monit; 2011 Aug; 33(4):393-7. PubMed ID: 21654349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem.
    Cirillo I; Vaccaro N; Balis D; Redman R; Matzke GR
    Antimicrob Agents Chemother; 2011 Mar; 55(3):1187-93. PubMed ID: 21199922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Toral D; Pedraz JL
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.